Cargando…

Immune System-Related Changes in Preclinical GL261 Glioblastoma under TMZ Treatment: Explaining MRSI-Based Nosological Imaging Findings with RT-PCR Analyses

SIMPLE SUMMARY: Glioblastoma (GB) is an aggressive brain tumour with poor survival. Tumour microenvironment is a key element in GB evolution and response to therapy. We assessed presence and phenotypes of microglia/macrophages in preclinical GL261-GB microenvironment under Temozolomide (TMZ) treatme...

Descripción completa

Detalles Bibliográficos
Autores principales:	Calero-Pérez, Pilar, Wu, Shuang, Arús, Carles, Candiota, Ana Paula
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8199490/ https://www.ncbi.nlm.nih.gov/pubmed/34071393 http://dx.doi.org/10.3390/cancers13112663

Ejemplares similares

Anti-PD-1 Immunotherapy in Preclinical GL261 Glioblastoma: Influence of Therapeutic Parameters and Non-Invasive Response Biomarker Assessment with MRSI-Based Approaches
por: Wu, Shuang, et al.
Publicado: (2020)

Unraveling response to temozolomide in preclinical GL261 glioblastoma with MRI/MRSI using radiomics and signal source extraction
por: Núñez, Luis Miguel, et al.
Publicado: (2020)

Successful Partnerships: Exploring the Potential of Immunogenic Signals Triggered by TMZ, CX-4945, and Combined Treatment in GL261 Glioblastoma Cells
por: Villamañan, Lucía, et al.
Publicado: (2021)

Targeting Protein Kinase CK2: Evaluating CX-4945 Potential for GL261 Glioblastoma Therapy in Immunocompetent Mice
por: Ferrer-Font, Laura, et al.
Publicado: (2017)

Metabolomics of Therapy Response in Preclinical Glioblastoma: A Multi-Slice MRSI-Based Volumetric Analysis for Noninvasive Assessment of Temozolomide Treatment
por: Arias-Ramos, Nuria, et al.
Publicado: (2017)

Improving the classification of brain tumors in mice with perturbation enhanced (PE)-MRSI
por: Simões, Rui V, et al.
Publicado: (2010)

Establishing Imaging Biomarkers of Host Immune System Efficacy during Glioblastoma Therapy Response: Challenges, Obstacles and Future Perspectives
por: Candiota, Ana Paula, et al.
Publicado: (2022)

Convective forces increase CXCR4-dependent glioblastoma cell invasion in GL261 murine model
por: Cornelison, R. Chase, et al.
Publicado: (2018)

Anthracycline-induced cytotoxicity in the GL261 glioma model system
por: Tavener, Amber M., et al.
Publicado: (2021)

A therapeutic cancer vaccine against GL261 murine glioma
por: Kindy, Mark S., et al.
Publicado: (2016)

Longitudinal [(18)F]GE-180 PET Imaging Facilitates In Vivo Monitoring of TSPO Expression in the GL261 Glioblastoma Mouse Model
por: Holzgreve, Adrien, et al.
Publicado: (2022)

Convex Non-Negative Matrix Factorization for Brain Tumor Delimitation from MRSI Data
por: Ortega-Martorell, Sandra, et al.
Publicado: (2012)

OKN-007 Increases temozolomide (TMZ) Sensitivity and Suppresses TMZ-Resistant Glioblastoma (GBM) Tumor Growth()()
por: Towner, Rheal A., et al.
Publicado: (2018)

Perfluorocarbon emulsions radiosensitise brain tumors in carbogen breathing mice with orthotopic GL261 gliomas
por: Feldman, Lisa A., et al.
Publicado: (2017)

Temporal and spatial modulation of the tumor and systemic immune response in the murine Gl261 glioma model
por: McKelvey, Kelly J., et al.
Publicado: (2020)

Pyk2/FAK Signaling Is Upregulated in Recurrent Glioblastoma Tumors in a C57BL/6/GL261 Glioma Implantation Model
por: Ortiz Rivera, Jescelica, et al.
Publicado: (2023)

Platinum-Based Nanoformulations for Glioblastoma Treatment: The Resurgence of Platinum Drugs?
por: Alfonso-Triguero, Paula, et al.
Publicado: (2023)

Anti-PD-1 checkpoint blockade monotherapy in the orthotopic GL261 glioma model: the devil is in the detail
por: Tritz, Zachariah P, et al.
Publicado: (2021)

TRPC5 mediates TMZ resistance in TMZ-resistant glioblastoma cells via NFATc3-P-gp pathway
por: Zou, Yan, et al.
Publicado: (2021)

Self-assembled angiopep-2 modified lipid-poly (hypoxic radiosensitized polyprodrug) nanoparticles delivery TMZ for glioma synergistic TMZ and RT therapy
por: Zong, Zhenkun, et al.
Publicado: (2019)

A New Pharmacokinetic Model Describing the Biodistribution of Intravenously and Intratumorally Administered Superparamagnetic Iron Oxide Nanoparticles (SPIONs) in a GL261 Xenograft Glioblastoma Model
por: Klapproth, Alexander P, et al.
Publicado: (2020)

Hsa_circ_0072309 enhances autophagy and TMZ sensitivity in glioblastoma
por: Yuan, Fanen, et al.
Publicado: (2022)

Stable luciferase expression does not alter immunologic or in vivo growth properties of GL261 murine glioma cells
por: Clark, Aaron J, et al.
Publicado: (2014)

GL261 luciferase-expressing cells elicit an anti-tumor immune response: an evaluation of murine glioma models
por: Sanchez, Victoria E., et al.
Publicado: (2020)

DCE@urLAB: a dynamic contrast-enhanced MRI pharmacokinetic analysis tool for preclinical data
por: Ortuño, Juan E, et al.
Publicado: (2013)

Embedding MRI information into MRSI data source extraction improves brain tumour delineation in animal models
por: Ortega-Martorell, Sandra, et al.
Publicado: (2019)

A New Pharmacokinetic Model Describing the Biodistribution of Intravenously and Intratumorally Administered Superparamagnetic Iron Oxide Nanoparticles (SPIONs) in a GL261 Xenograft Glioblastoma Model [Corrigendum]
Publicado: (2020)

Convection-enhanced delivery of temozolomide and whole cell tumor immunizations in GL261 and KR158 experimental mouse gliomas
por: Enríquez Pérez, Julio, et al.
Publicado: (2020)

Synthesis and Validation of a Bioinspired Catechol-Functionalized Pt(IV) Prodrug for Preclinical Intranasal Glioblastoma Treatment
por: Mao, Xiaoman, et al.
Publicado: (2022)

Metronomic cyclophosphamide eradicates large implanted GL261 gliomas by activating antitumor Cd8(+) T-cell responses and immune memory
por: Wu, Junjie, et al.
Publicado: (2015)

A new anti-glioma therapy, AG119: pre-clinical assessment in a mouse GL261 glioma model
por: Towner, Rheal A., et al.
Publicado: (2015)

Live-cell calcium imaging of adherent and non-adherent GL261 cells reveals phenotype-dependent differences in drug responses
por: Strong, Averey D., et al.
Publicado: (2017)

Author Correction: GL261 luciferase-expressing cells elicit an anti-tumor immune response: an evaluation of murine glioma models
por: Sanchez, Victoria E., et al.
Publicado: (2022)

Irradiation-Modulated Murine Brain Microenvironment Enhances GL261-Tumor Growth and Inhibits Anti-PD-L1 Immunotherapy
por: Garbow, Joel R., et al.
Publicado: (2021)

SapC-DOPS-induced lysosomal cell death synergizes with TMZ in glioblastoma
por: Wojton, Jeffrey, et al.
Publicado: (2014)

Gasdermin D Is a Novel Prognostic Biomarker and Relates to TMZ Response in Glioblastoma
por: Liu, Junhui, et al.
Publicado: (2021)

Nosology of Zanzibar
Publicado: (1872)

Positive Nosology
Publicado: (1849)

Remarks on Nosology
Publicado: (1810)

Positive Nosology
Publicado: (1847)

Cannot write session to /tmp/vufind_sessions/sess_dtj0sfvkevf5mqfajhktmjdr23